E. M. De-villiers, Cross-roads in the classification of papillomaviruses, Virology, vol.445, 2013.

V. Bouvard, R. Baan, K. Straif, Y. Grosse, B. Secretan et al., WHO International Agency for Research on Cancer Monograph Working Group. A review of human carcinogens-Part B: biological agents, Lancet Oncol, vol.10, pp.321-323, 2009.

S. De-sanjose, W. G. Quint, L. Alemany, D. T. Geraets, J. E. Klaustermeier et al., Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study, Lancet Oncol, vol.11, issue.10, pp.70230-70238, 2010.

D. Vuyst, H. Clifford, G. M. Nascimento, M. C. Madeleine, M. M. Franceschi et al., Prevalence and type distribution of

M. Scheffner, J. M. Huibregtse, R. D. Vierstra, and P. M. Howley, The HPV-16 E6 and E6-AP complex functions as a ubiquitinprotein ligase in the ubiquitination of p53, Cell, vol.75, pp.495-505, 1993.

S. Chellappan, V. B. Kraus, B. Kroger, K. Munger, P. M. Howley et al., Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product, Proc Natl Acad Sci, vol.89, pp.4549-53, 1992.

C. Gao, M. M. Pan, Y. J. Lei, L. Q. Tian, H. Y. Jiang et al., A point mutation in the DNA-binding domain of HPV-2 E2 protein increases its DNA-binding capacity and reverses its transcriptional regulatory activity on the viral early promoter, BMC Mol Biol, vol.13, p.5, 2012.

B. Bhattacharjee and S. Sengupta, CpG methylation of HPV 16 LCR at E2 binding site proximal to P97 is associated with cervical cancer in presence of intact E2, Virology, vol.354, pp.280-285, 2006.

E. Jacquin, A. Baraquin, R. Ramanah, X. Carcopino, A. Morel et al., Methylation of human papillomavirus Type 16 CpG sites at E2-binding site 1 (E2BS1), E2BS2, and the Sp1-binding site in cervical cancer samples as determined by high-resolution melting analysis-PCR, J Clin Microbiol, vol.51, pp.3207-3222, 2013.

S. Vinokurova and M. Doeberitz, Differential methylation of the HPV 16 upstream regulatory region during epithelial differentiation and neoplastic transformation, PLoS One, vol.6, 2011.
DOI : 10.1371/journal.pone.0024451
URL : https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0024451&type=printable

D. Das-ghosh, B. Bhattacharjee, S. Sen, L. Premi, I. Mukhopadhyay et al., Some novel insights on HPV16 related cervical cancer pathogenesis based on analyses of LCR methylation, viral load, E7 and E2/E4 expressions, PLoS One, vol.7, p.44678, 2012.

T. W. Leung, S. S. Liu, R. C. Leung, M. M. Chu, A. N. Cheung et al., HPV 16 E2 binding sites 1 and 2 become more methylated than E2 binding site 4 during cervical carcinogenesis, J Med Virol, vol.87, pp.1022-1055, 2015.
DOI : 10.1002/jmv.24129

S. Jeon and P. F. Lambert, Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis, Proc Natl Acad Sci, vol.92, pp.1654-1662, 1995.

K. Gupta, A. Kumar, and M. , HPVbase-a knowledgebase of viral integrations, methylation patterns and microRNAs aberrant expression: as potential biomarkers for Human papillomaviruses mediated carcinomas, Sci Rep, vol.5, p.12522, 2015.

Q. Tian, Y. Li, F. Wang, Y. Li, J. Xu et al., MicroRNA detection in cervical exfoliated cells as a triage for human papillomavirus-positive women, J Natl Cancer Inst, vol.106, p.241, 2014.

H. M. Jung, B. L. Phillips, and E. K. Chan, miR-375 activates p21 and suppresses telomerase activity by coordinately regulating HPV E6/E7, E6AP, CIP2A, and 14-3-3?, Mol Cancer, vol.13, p.80, 2014.
DOI : 10.1186/1476-4598-13-80
URL : https://molecular-cancer.biomedcentral.com/track/pdf/10.1186/1476-4598-13-80

F. Wang, Y. Li, J. Zhou, J. Xu, C. Peng et al., miR-375 is down-regulated in squamous cervical cancer and inhibits cell migration and invasion via targeting transcription factor SP1, Genes Chromosomes Cancer, vol.179, pp.56-68, 2011.
DOI : 10.1016/j.ajpath.2011.07.037
URL : http://europepmc.org/articles/pmc3204087?pdf=render

S. M. Wilting, W. Verlaat, A. Jaspers, N. A. Makazaji, R. Agami et al., Methylationmediated transcriptional repression of microRNAs during cervical carcinogenesis, Epigenetics, vol.8, pp.220-228, 2013.

C. Yee, I. Krishnan-hewlett, C. C. Baker, R. Schlegel, and P. M. Howley, Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines, Am J Pathol, vol.119, pp.361-367, 1985.

J. Chen, Y. Xue, M. Poidinger, T. Lim, S. H. Chew et al., Mapping of HPV transcripts in four human cervical lesions using RNAseq suggests quantitative rearrangements during carcinogenic progression, Virology, pp.462-463, 2014.

M. Stich, L. Ganss, J. Puschhof, E. S. Prigge, M. Reuschenbach et al., 5-aza-2?-deoxycytidine (DAC) treatment downregulates the HPV E6 and E7 oncogene expression and blocks neoplastic growth of HPV-associated cancer cells, Oncotarget, 2016.

,

R. J. Klose and A. P. Bird, Genomic DNA methylation: the mark and its mediators, Trends Biochem Sci, vol.31, pp.89-97, 2006.

J. De-castro-arce, E. Göckel-krzikalla, and F. Rösl, Silencing of multi-copy HPV16 by viral self-methylation and chromatin occlusion: a model for epigenetic virus-host interaction, Hum Mol Genet, vol.21, pp.1693-705, 2012.

F. Rösl, A. Arab, B. Klevenz, and H. Zur-hausen, The effect of DNA methylation on gene regulation of human papillomaviruses, J Gen Virol, vol.74, pp.791-801, 1993.

Y. Xue, D. Lim, L. Zhi, P. He, J. P. Abastado et al., Loss of HPV16 E2 protein expression without disruption of the E2 ORF correlates with carcinogenic progression, Open Virol J, vol.6, pp.163-72, 2012.

F. Thierry and M. Yaniv, The BPV1-E2 trans-acting protein can be either an activator or a repressor of the HPV18 regulatory region, EMBO J, vol.6, pp.3391-3398, 1987.

H. Guan, B. Mi, Y. Li, W. Wu, P. Tan et al., Decitabine represses osteoclastogenesis through inhibition of RANK and NF-?B, Cell Signal, vol.27, pp.969-77, 2015.

A. Wouters, B. Balastik, M. Shapiro-koss, C. Zhang, H. Diruscio et al.,

C. , EBP? deregulation results in differentiation arrest in acute myeloid leukemia, J Clin Invest, vol.122, pp.4490-504, 2012.

K. L. Bennett, B. Hackanson, L. T. Smith, C. D. Morrison, J. C. Lang et al., Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma, Cancer Res, vol.67, pp.4657-64, 2007.

T. M. Filtz, W. K. Vogel, and M. Leid, Regulation of transcription factor activity by interconnected post-translational modifications, Trends Pharmacol Sci, vol.35, pp.76-85, 2014.

H. Piotrowska and P. P. Jagodzinski, Glucocorticoid receptor alpha and beta variant expression is associated with ASF/ SF2 splicing factor upregulation in HT-29 colon cancer and MCF-7 breast carcinoma cells, Arch Med Res, vol.40, pp.156-62, 2009.

M. Mcfarlane, A. I. Macdonald, A. Stevenson, and S. V. Graham, Human papillomavirus 16 oncoprotein expression is controlled by the cellular splicing factor SRSF2 (SC35), J Virol, vol.89, pp.5276-87, 2015.

M. W. Luczak and P. P. Jagodzinski, Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells, Cancer Lett, vol.272, pp.53-60, 2008.

H. Iwakawa and Y. Tomari, The functions of MicroRNAs: mRNA decay and translational repression, Trends Cell Biol, vol.25, pp.651-65, 2015.

J. Mazar, D. Deblasio, S. S. Govindarajan, S. Zhang, and R. J. Perera, Epigenetic regulation of microRNA-375 and its role in melanoma development in humans, FEBS Lett, vol.585, pp.2467-76, 2011.

A. Yeung, C. L. Tsang, W. P. Tsang, T. Y. Co, N. N. Yau et al., HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53, Oncol Rep, vol.24, pp.1599-604, 2010.

M. E. Mclaughlin-drubin, C. P. Crum, and K. Münger, Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming, Proc Natl Acad Sci U S A, vol.108, pp.2130-2135, 2011.

C. H. Hsu, K. L. Peng, H. C. Jhang, C. H. Lin, S. Y. Wu et al., The HPV E6 oncoprotein targets histone methyltransferases for modulating specific gene transcription, Oncogene, vol.31, pp.2335-2384, 2012.

D. Costa, Z. J. Jolly, C. Androphy, E. J. Mercer, A. Matthews et al., Transcriptional repression of E-cadherin by human papillomavirus type 16 E6, PLoS One, vol.7, p.48954, 2012.

A. Yeung, C. L. Tsang, T. Y. Yau, P. L. Kwok, and T. T. , Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway, Oncogene, vol.30, pp.2401-2411, 2011.

D. Greco, N. Kivi, K. Qian, S. K. Leivonen, P. Auvinen et al., Human papillomavirus 16 E5 modulates the www.impactjournals.com/oncotarget expression of host microRNAs, PLoS One, vol.6, 2011.

Y. Gómez-gómez, J. Organista-nava, and P. Gariglio, Deregulation of the miRNAs expression in cervical cancer: human papillomavirus implications, Biomed Res Int, p.407052, 2013.

S. Liu, L. Song, H. Yao, L. Zhang, D. Xu et al., MiR-375 is epigenetically downregulated by HPV-16 E6 mediated DNMT1 upregulation and modulates EMT of cervical cancer cells by suppressing lncRNA MALAT1, PLoS One, vol.11, 2016.

J. He, Y. Ji, A. Li, Q. Zhang, W. Song et al., MiR122 directly inhibits human papillomavirus E6 gene and enhances interferon signaling through blocking suppressor of cytokine signaling 1 in SiHa cells, PLoS One, vol.9, p.108410, 2014.

L. Lin, Q. Cai, X. Zhang, H. Zhang, Y. Zhong et al., Two less common human microRNAs miR-875 and miR3144 target a conserved site of E6 oncogene in most highrisk human papillomavirus subtypes, Protein Cell, vol.6, pp.575-88, 2015.

B. Bernard, J. L. Prétet, J. F. Charlot, and C. Mougin, Human papillomaviruses type 16+ and 18+ cervical carcinoma cells are sensitive to staurosporine-mediated apoptosis, Biol Cell, vol.95, pp.17-26, 2003.

F. Hirchaud, F. Hermetet, M. Ablise, S. Fauconnet, D. A. Vuitton et al., Isoliquiritigenin induces caspasedependent apoptosis via downregulation of HPV16 E6 expression in cervical cancer Ca Ski cells, Planta Med, vol.79, pp.1628-1663, 2013.

G. Reid, S. C. Kao, N. Pavlakis, H. Brahmbhatt, J. Macdiarmid et al., Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer, Epigenomics, vol.8, pp.1079-85, 2016.

V. Valdespino and P. M. Valdespino, Potential of epigenetic therapies in the management of solid tumors, Cancer Manag Res, vol.7, pp.241-51, 2015.

Z. Wang, V. Murigneux, L. Hir, and H. , Transcriptomewide modulation of splicing by the exon junction complex, Genome Biol, vol.15, p.551, 2014.